12,372 trials
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 — 1.469; 1.372; 1.455 Liters
Sore Throat Due to a Common Cold
Primary: Change From Baseline Sore Throat Pain Intensity — -27.4; -26.9 mm
SURGICAL SITE INFECTION
Primary: Surgical Site Infection — 6; 3 participants — p=<0.05
Gaucher Disease
Primary: Change From Baseline in Spleen Volume Measured by MRI. — -26.91; -38.01 percentage of change — p=<0.0001
Cystic Fibrosis
Primary: Number of Participants With Treatment-emergent Adverse Events — 278; 176; 85; 61 participants
Autism
Primary: Percent Change of ABC - Irritability Subscale Score — -44.5 percent change in scores
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.3; -3.3; -3.8; -2.2 units on a scale
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 109; 33 Subjects
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and…
Osteoporosis
Primary: Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III. — 1.002; 0.990 Percentage Change — p=0.010
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 12; 1 Subjects
Neisseria Meningitidis · Haemophilus Influenzae Type b
Primary: Number of Subjects With Anti- Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 0.15 Microgram Per Milliliter — 116; 49; 46; 60…
Arthritis, Juvenile Idiopathic
Primary: Percentage of Participants With an American College of Rheumatology Pediatric 30 (ACR Pedi 30) Response at Week 12 — 88.6 Percentage of participants
Perennial Allergic Rhinitis
Primary: Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline — 183.2; 171.7; 173.1; 172.8 mcg•h/dL